Dr. Majd El-Harasis presented data at the American Heart Association’s Scientific Sessions in Philadelphia, supporting the use of AF ablation for most patients with genetic forms of AFib. However, he pointed out that patients with LMNA variants had significantly higher rates of arrhythmia recurrence.
His abstract, “Ablation for atrial fibrillation in patients with rare pathogenic variants in arrhythmia and cardiomyopathy genes,” was selected for a platform presentation. This gave him the opportunity to present to a wide audience the Vanderbilt AFib research team’s work supporting the continued use of AF ablation for most patients with rare pathogenic variants, including those with TTN variants.
However, research found that AF ablation for a small subset of patients, specifically those with pathogenic variants in the LMNA gene, may be at significantly higher risk of arrhythmia recurring after ablation.